EGM Statement

Ardana PLC
12 October 2006



                                   Ardana plc



                                 Result of EGM




Edinburgh, UK, 12 October 2006 - Ardana plc (LSE: ARA.L) ('Ardana or the Company
') confirms that all resolutions put to the Extraordinary General Meeting held
on 12 October 2006 were duly passed.


The 9,585,380 New Ordinary Shares of 1 penny each in the Company to be issued
pursuant to the Placing and Open Offer at a price of 115 pence per share are
expected to be admitted to the Official List and to trading on the London Stock
Exchange's main market for listed securities tomorrow, 13 October 2006.
Following admission of the New Ordinary Shares, there will be in issue
65,268,939 Ordinary Shares in the Company.


Full details of the Placing and Open Offer are set out in the prospectus
published on 20 September 2006 (the 'Prospectus').


Terms defined in the Prospectus have the same meaning in this announcement.  A
copy of the Prospectus has been submitted to the FSA, and is available for
inspection at the FSA's Document Viewing Facility, which is situated at:
Financial Service Authority, 25 The North Colonnade, Canary Wharf, London E14
5HS.


Monies raised by the Placing and Open Offer will be used to develop Oral GHS
(EP01572) the Company's oral growth hormone secretagogue and also to launch and
promote Emselex(R), a treatment for overactive bladder, for which agreement has
been reached with Novartis Pharmaceuticals UK Limited to grant Ardana sole and
exclusive rights to launch and promote the product in the UK for a ten year
term.


Enquiries:
Ardana plc
[phone]
Dr Maureen Lindsay, Chief Executive Officer
Graham Lee, Chief Financial Officer


Piper Jaffray Ltd.
[phone]
Jamie Adams
James Steel


Financial Dynamics
[phone]
Julia Phillips
John Gilbert



About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $25.5
billion market.


Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
out-licensing to maintain a robust pipeline.



  • Ardana's lead products are summarised below:

  • Emselex(R), a treatment for overactive bladder for which Ardana has sole
    and exclusive promotion rights in the UK and will be launched in
    collaboration with Novartis Pharmaceuticals UK Limited;
  • StriantTM SR, a testosterone replacement therapy for which Ardana has
    marketing rights in Europe, has been launched by Ardana through its own
    sales force in the UK and partners in various European countries, as a
    treatment for men with confirmed hypogonadism;
  • Teverelix LA, in development for three initial indications: prostate
    cancer and benign prostatic hyperplasia (both indications are at the phase
    II stage), and endometriosis (currently in phase I);
  • Testosterone Cream, a transdermal testosterone delivery system in phase II
    for the treatment of male hypogonadism;
  • Invicorp(R), an injectable combination drug treatment for erectile
    dysfunction, already approved in Denmark and for which Ardana has marketing
    and manufacturing rights in Europe. Launch is expected in H2 2006;



In addition to the above Ardana has a strong portfolio of follow-on products in
development.



For further information please see www.ardana.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange